Sanofi’s shift to immunology, AI-driven R&D, and strong pipeline offset risks from patent cliffs and legal issues. See why ...

U.S. sales of Eylea HD and Eylea, treatments for eye conditions like wet age-related macular degeneration, decreased 25% in ...

France's Sanofi said on Thursday that it expects annual sales to grow by high single-digit percentage, helped by strong ...

In November 2024, Regeneron and Sanofi’s Dupixent gained FDA approval for COPD, marking its sixth U.S. indication since its first use for atopic dermatitis seven years ago.

Next-gen COPD drug from Sanofi, Regeneron shows mixed results in Phase 3 trials The companies are looking for their next Dupixent Anna Yeo/STAT By Andrew Joseph May 30, 2025 Europe Correspondent ...

Drugmaker Sanofi said on Thursday it believes the impact from U.S. tariffs to be manageable as it raised its sales growth ...

Sanofi and Regeneron Pharmaceuticals reported mixed results for two late-stage trials of an experimental respiratory drug they are jointly developing, with one study meeting the primary goal and a ...

Regeneron Pharmaceuticals and Sanofi announced that their Phase 3 clinical trial, AERIFY-1, showed a significant 27% reduction in moderate to severe exacerbations of COPD in former smokers treated ...